StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3035% above fair value
$93.04−2.76 (-2.88%)

Close on Nov 19, 2026Market cap $10.56BP/E 27.4Yield –

Halozyme Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Halozyme Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $597.20M, down 12.5% year over year. For fiscal 2025 it was $469.01M, down 15.0% from the year before. The highest annual figure on record is $551.48M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$469.01M-15.0%
FY2024Dec 31, 2024$551.48M+63.4%
FY2023Dec 31, 2023$337.57M+26.2%
FY2022Dec 31, 2022$267.53M-3.0%
FY2021Dec 31, 2021$275.90M+91.3%
FY2020Dec 31, 2020$144.26M–
FY2019Dec 31, 2019-$67.61M–
FY2018Dec 31, 2018-$69.33M-185.6%
FY2017Dec 31, 2017$81.00M–
FY2016Dec 31, 2016-$83.21M–
FY2015Dec 31, 2015-$27.45M–
FY2014Dec 31, 2014-$63.04M–
FY2013Dec 31, 2013-$80.43M–
FY2012Dec 31, 2012-$53.63M–
FY2011Dec 31, 2011-$19.84M–
FY2010Dec 31, 2010-$54.26M–
FY2009Dec 31, 2009-$58.46M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$287.65M+42.1%
Q1 FY2026Mar 31, 2026$184.52M+30.4%
Q4 FY2025Dec 31, 2025-$92.89M-152.9%
Q3 FY2025Sep 30, 2025$217.92M+33.5%
Q2 FY2025Jun 30, 2025$202.44M+72.7%
Q1 FY2025Mar 31, 2025$141.54M+48.1%
Q4 FY2024Dec 31, 2024$175.50M+73.7%
Q3 FY2024Sep 30, 2024$163.20M+84.9%
Q2 FY2024Jun 30, 2024$117.24M+24.1%
Q1 FY2024Mar 31, 2024$95.54M+77.6%
Q4 FY2023Dec 31, 2023$101.04M+35.6%
Q3 FY2023Sep 30, 2023$88.28M+6.0%
Q2 FY2023Jun 30, 2023$94.46M+177.3%
Q1 FY2023Mar 31, 2023$53.80M-28.9%
Q4 FY2022Dec 31, 2022$74.51M+31.8%
Q3 FY2022Sep 30, 2022$83.29M+10.2%
Q2 FY2022Jun 30, 2022$34.06M-63.4%
Q1 FY2022Mar 31, 2022$75.67M+49.1%
Q4 FY2021Dec 31, 2021$56.53M-27.2%
Q3 FY2021Sep 30, 2021$75.59M+87.6%
Q2 FY2021Jun 30, 2021$93.05M+214.8%
Q1 FY2021Mar 31, 2021$50.74M–
Q4 FY2020Dec 31, 2020$77.62M–
Q3 FY2020Sep 30, 2020$40.30M–
Q2 FY2020Jun 30, 2020$29.56M–
Q1 FY2020Mar 31, 2020-$3.22M-208.7%
Q4 FY2019Dec 31, 2019-$32.06M–
Q3 FY2019Sep 30, 2019-$24.54M–
Q2 FY2019Jun 30, 2019-$13.98M–
Q1 FY2019Mar 31, 2019$2.97M–
Q4 FY2018Dec 31, 2018-$71.00K-100.1%
Q3 FY2018Sep 30, 2018-$25.47M-415.4%
Q2 FY2018Jun 30, 2018-$20.07M–
Q1 FY2018Mar 31, 2018-$23.71M–
Q4 FY2017Dec 31, 2017$125.93M–
Q3 FY2017Sep 30, 2017$8.08M–
Q2 FY2017Jun 30, 2017-$25.48M–
Q1 FY2017Mar 31, 2017-$27.53M–
Q4 FY2016Dec 31, 2016-$22.58M–
Q3 FY2016Sep 30, 2016-$22.74M–

More Halozyme Therapeutics figures

See a number that looks wrong?